Group Leader, Immunotherapy for infectious diseases
Room: P101d
Phone: +49.531.391.5764
email: f.bertoglio(at)tu-braunschweig.de
ORCID (Original Citation ID) 0000-0001-6477-1785
Research interests
My passion is to combat bacterial and viral infectious diseases with 21st-century biologicals. The main focus resides on recombinant antibodies produced from our extremely diverse phage display libraries of human antibodies, and by exploring the vast new possibilities offered by genetic engineering today that enable to fight pathogens with molecular structures from our own bodies in ways that exceed the capabilities of our immune system. Recent examples are the development of anti-Staphylococcus aureus coagulase antibodies or the development of an Fc-silenced antibody against the pandemic virus SARS-CoV-2 that reached clinical use in very short time.
Curriculum vitae
2013 B.Sc, Biology, Biomolecular track, University of Pavia, Italy
2015 M.Sc, Molecular Biology and Genetics, University of Pavia, Italy
2017 Research internship at Centre for Infectious and Inflammatory Diseases (CIID), Institute of Biosciences and Technology (IBT), Texas A&M University Health Science Centre, Houston, USA
2020 Doctoral degree, Biomolecular Sciences and Biotechnology, School for Advanced Studies IUSS and University of Pavia, Italy
2020-2022 Research Associate, Dept. of Biotechnology, Technische Universität Braunschweig, Germany
2022-2023 Lead of Protein Engineering, Choose Life Biotech SA, Bellinzona, Switzerland
2024-ongoing Group leader and Research Associate, Dept. of Medical Biotechnology, Technische Universität Braunschweig, Germany
Honors and Awards
2015 Competitive Erasmus traineeship scholarship from University of Pavia
2016 Competitive Erasmus traineeship “Bet for Jobs” scholarship from University of Pavia
2020 Awardee of a research travel grant from Italian Society of Molecular Biology and Biochemistry (SIB)
2020 Innovation Award of the State of Lower Saxony, Germany (as part of the CORAT Team)
Patents
US patent No.: US 2020/0283508, Composition and use of Fibrinogen binding motif present in Efb and Coa for therapeutics and vaccines against Staphylococcus aureus (priority date 2020)
Patent application EP3919126A1: "Therapeutic antibodies with neutralizing activity against sars-cov-2 glycoprotein s" (priority date 2020)
Italian patent No.: 102018000020242, Three-dimensional substrate for microbial cultures (now extended WO-2020128965-A1) (priority date 2018)
Publications
Antibody field-related publications (most relevant ones at the beginning)
1. Bertoglio F§, Ko Y-P, Thomas S, Giordano L, Scommegna FR, Meier D, Helmsig Polten S, Becker M, Arora S, Hust M, Höök M, Visai L. Antibodies to Coagulase of Staphylococcus aureus crossreact to Efb and reveal different binding of shared Fibrinogen binding repeats. Front Immunol. 2023 Sep 27;14:1221108. doi.org/10.3389/fimmu.2023.1221108.
2. Schubert M*, Bertoglio F*, Steinke S, Heine PA, Ynga-Durand MA, Maass H, Sammartino JC, Cassaniti I, Zuo F, Du L, Korn J, Milošević M, Wenzel EV, Krstanović F, Polten S, Pribanić-Matešić M, Brizić I, Baldanti F, Hammarström L, Dübel S, Šustić A, Marcotte H, Strengert M, Protić A, Piralla A, Pan-Hammarström Q, Čičin-Šain L, Hust M. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. BMC Med. 2022 Mar 3;20(1):102. doi.org/10.1186/s12916-022-02312-5.
3. Bertoglio F*, Fühner V*, Ruschig M*, Heine PA*, Abassi L*, Klünemann T*, Rand U*, Meier D, Langreder N, Steinke S, Ballmann R, Schneider KT, Roth KDR, Kuhn P, Riese P, Schäckermann D, Korn J, Koch A, Chaudhry MZ, Eschke K, Kim Y, Zock-Emmenthal S, Becker M, Scholz M, Moreira GMSG, Wenzel EV, Russo G, Garritsen HSP, Casu S, Gerstner A, Roth G, Adler J, Trimpert J, Hermann A, Schirrmann T, Dübel S, Frenzel A, Van den Heuvel J, Čičin-Šain L, Schubert M, Hust M. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Rep. 2021 Jul 27;36(4):109433. doi.org/10.1016/j.celrep.2021.109433
4. Bertoglio F*, Meier D*, Langreder N*, Steinke S*, Rand U*, Simonelli L*, Heine PA, Ballmann R, Schneider KT, Roth KDR, Ruschig M, Riese P, Eschke K, Kim Y, Schäckermann D, Pedotti M, Kuhn P, Zock-Emmenthal S, Wöhrle J, Kilb N, Herz T, Becker M, Grasshoff M, Wenzel EV, Russo G, Kröger A, Brunotte L, Ludwig S, Fühner V, Krämer SD, Dübel S, Varani L, Roth G, Čičin-Šain L, Schubert M, Hust M. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021 Mar 11;12(1):1577. doi.org/10.1038/s41467-021-21609-2
5. Zuo F, Cao Y, Sun R, Wang Q, Simonelli L, Du L, Bertoglio F, Schubert M, Guerra C, Cavalli A, Hust M, Robbiani DF, Varani L, Abolhassani H, Xie XS, Hammarström L, Marcotte H, Pan-Hammarström Q.Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants.J Virol. 2025 Jan 31;99(1):e0174024. doi.org/10.1128/jvi.01740-24. Epub 2024 Dec 4.
6. Marcotte H, Cao Y, Zuo F, Simonelli L, Sammartino JC, Pedotti M, Sun R, Cassaniti I, Hagbom M, Piralla A, Yang J, Du L, Percivalle E, Bertoglio F, Schubert M, Abolhassani H, Sherina N, Guerra C, Borte S, Rezaei N, Kumagai-Braesch M, Xue Y, Su C, Yan Q, He P, Grönwall C, Klareskog L, Calzolai L, Cavalli A, Wang Q, Robbiani DF, Hust M, Shi Z, Feng L, Svensson L, Chen L, Bao L, Baldanti F, Xiao J, Qin C, Hammarström L, Yang X, Varani L, Xie XS, Pan-Hammarström Q. Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages. Proc Natl Acad Sci U S A. 2024 Jan 16;121(3):e2315354120. doi.org/10.1073/pnas.2315354120.
7. Zuo F, Cao Y, Sun R, Yisimayi A, Du L, Bertoglio F, Schubert M, Guerra C, Cavalli A, Hust M, Robbiani DF, Abolhassani H, Xie XS, Hammarström L, Marcotte H, Pan-Hammarström Q. Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86. Lancet Infect Dis. 2024 Jan;24(1):e7-e9. doi.org/10.1016/S1473-3099(23)00732-6.
8. Metzdorf K, Jacobsen H, Kim Y, Teixeira Alves LG, Kulkarni U, Eschke K, Chaudhry MZ, Hoffmann M, Bertoglio F, Ruschig M, Hust M, Cokarić Brdovčak M, Materljan J, Šustić M, Krmpotić A, Jonjić S, Widera M, Ciesek S, Pöhlmann S, Landthaler M, Čičin-Šain L. A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants. Front Immunol. 2024 Jul 25;15:1383086. doi.org/10.3389/fimmu.2024.1383086.
9. Abassi L, Bertoglio F, Mačak Šafranko Ž, Schirrmann T, Greweling-Pils M, Seifert O, Khan F, Katzmarzyk M, Jacobsen H, Gödecke N, et al. Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses. 2023; 15(11):2153. doi.org/10.3390/v15112153
10. Steinke, S., Roth, K.D.R., Englick, R., Langreder, N., Ballmann, R., Fühner, V., Zilkens, K.J.K., Moreira, G.M.S.G., Koch, A., Russo, G., Schubert, M., Bertoglio, F., Heine, P.A. & Hust, M. Mapping Epitopes by Phage Display. Methods Mol Biol. 2023;2702:563-585. doi.org/10.1007/978-1-0716-3381-6_28.
11. Langreder, N., Schäckermann, D., Unkauf, T., Schubert, M., Frenzel, A., Bertoglio, F. & Hust, M. Antibody Affinity and Stability Maturation by Error-Prone PCR. Methods Mol Biol. 2023;2702:395-410. doi.org/10.1007/978-1-0716-3381-6_20.
12. Heine, P.A., Ruschig, M., Langreder, Wenzel, E.V., Schubert, M., Bertoglio, F. & Hust, M. Antibody Selection in Solution Using Magnetic Beads. Methods Mol Biol. 2023;2702:261-274. doi.org/10.1007/978-1-0716-3381-6_13.
13. Steinke, S., Roth, K.D.R., Ruschig, Langreder, N., Polten, S., Schneider, K.-T., Ballmann, R., Russo, G., Zilkens, K.J.K., Schubert, M., Bertoglio, F. & Hust, M. Antibody Selection via Phage Display in Microtiter Plates. Methods Mol Biol. 2023;2702:247-260. doi.org/10.1007/978-1-0716-3381-6_12.
14. Ruschig, M., Heine, P.A., Fühner, V., Zilkens, K.J.K., Steinke, S., Schubert, M., Bertoglio, F. & Hust, M. Construction of Human Immune and Naive scFv Phage Display Libraries. Methods Mol Biol. 2023;2702:15-37. doi.org/10.1007/978-1-0716-3381-6_2.
15. Antunes A, Alvarez-Vallina L, Bertoglio F, Bouquin N, Cornen S, Duffieux F, Ferré P, Gillet R, Jorgensen C, Leick MB, Maillère B, Negre H, Pelegrin M, Poirier N, Reusch D, Robert B, Serre G, Vicari A, Villalba M, Volpers C, Vuddamalay G, Watier H, Wurch T, Zabeau L, Zielonka S, Zhang B, Beck A, Martineau P. 10th antibody industrial symposium: new developments in antibody and adoptive cell therapies. MAbs. 2023 Jan-Dec;15(1):2211692. doi.org/10.1080/19420862.2023.2211692.
16. Zuo F, Sun R, Abolhassani H, Du L, Wang Y, Vlachiotis S, Bertoglio F, Schubert M, Rezaei N, Chavoshzadeh Z, Guerra C, Cavalli A, Andréll J, Kumagai-Braesch M, Xue Y, Cao Y, Hust M, Robbiani DF, Xie XS, Hammarström L, Marcotte H, Pan-Hammarström Q. Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1. Lancet Reg Health West Pac. 2023 Apr;33:100762. doi.org/10.1016/j.lanwpc.2023.100762. Epub 2023 Apr 12.
17. Jaron M, Lehky M, Zarà M, Zaydowicz CN, Lak A, Ballmann R, Heine PA, Wenzel EV, Schneider KT, Bertoglio F, Kempter S, Köster RW, Barbieri SS, van den Heuvel J, Hust M, Dübel S, Schubert M. Baculovirus-Free SARS-CoV-2 Virus-like Particle Production in Insect Cells for Rapid Neutralization Assessment. Viruses. 2022 Sep 20;14(10):2087. doi.org/10.3390/v14102087.
18. Brlić PK, Pavletić M, Lerga M, Krstanović F, Matešić MP, Miklić K, Malić S, Mikša L, Pajcur M, Peruč D, Schubert M, Bertoglio F, Arapović J, Protić A, Šustić A, Milošević M, Šain LČ, Jonjić S, Lisnić VJ, Brizić I. SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study. Viruses. 2022 Sep 4;14(9):1966. doi.org/10.3390/v14091966.
19. Geisen UM, Rose R, Neumann F, Ciripoi M, Vullriede L, Reid HM, Berner DK, Bertoglio F, Hoff P, Hust M, Longardt AC, Lorentz T, Martini GR, Saggau C, Schirmer JH, Schubert M, Sümbül M, Tran F, Voß M, Zeuner R, Morrison PJ, Bacher P, Fickenscher H, Gerdes S, Peipp M, Schreiber S, Krumbholz A, Hoyer BF. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade. J Med Virol. 2022 Dec;94(12):5780-5789. doi.org/10.1002/jmv.28063. Epub 2022 Aug 19.
20. Ballmann R, Hotop SK, Bertoglio F, Steinke S, Heine PA, Chaudhry MZ, Jahn D, Pucker B, Baldanti F, Piralla A, Schubert M, Čičin-Šain L, Brönstrup M, Hust M, Dübel S. ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein. Viruses. 2022 Jun 17;14(6):1326. doi.org/10.3390/v14061326.
21. Zuo F*, Abolhassani H*, Du L*, Piralla A*, Bertoglio F, de Campos-Mata L, Wan H, Schubert M, Cassaniti I, Wang Y, Sammartino JC, Sun R, Vlachiotis S, Bergami F, Kumagai-Braesch M, Andréll J, Zhang Z, Xue Y, Wenzel EV, Calzolai L, Varani L, Rezaei N, Chavoshzadeh Z, Baldanti F, Hust M, Hammarström L, Marcotte H, Pan-Hammarström Q. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun. 2022 May 13;13(1):2670. doi.org/10.1038/s41467-022-30340-5.
22. Cokarić Brdovčak M, Materljan J, Šustić M, Ravlić S, Ružić T, Lisnić B, Miklić K, Brizić I, Pribanić Matešić M, Juranić Lisnić V, Halassy B, Rončević D, Knežević Z, Štefan L, Bertoglio F, Schubert M, Čičin-Šain L, Markotić A, Jonjić S, Krmpotić A. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. Eur J Immunol. 2022 Jun;52(6):936-945. doi.org/10.1002/eji.202249823. Epub 2022 Mar 31
23. Pribanić Matešić M, Kučan Brlić P, Lenac Roviš T, Mačak Šafranko Ž, Chaouat AE, Miklić K, Malić S, Ivanković N, Schubert M, Bertoglio F, Markotić A, Mandelboim O, Jonjić S, Brizić I.Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins. Viruses. 2022 Feb 21;14(2):443. doi.org/10.3390/v14020443.
24. Sevenich M, Thul E, Lakomek NA, Klünemann T, Schubert M, Bertoglio F, van den Heuvel J, Petzsch P, Mohrlüder J, Willbold D. Phage Display-Derived Compounds Displace hACE2 from Its Complex with SARS-CoV-2 Spike Protein. Biomedicines. 2022 Feb 14;10(2):441.https://doi.org/10.3390/biomedicines10020441.
25. Kim Y*, Zheng X*, Eschke K*, Chaudhry MZ*, Bertoglio F, Tomic A, Hoffmann M, Bar-On Y, Boehme J, Bruder D, Ebensen T, Brunotte L, Ludwig S, Messerle M, Guzmán C, Mandelboim O, Hust M, Pöhlmann S, Jonjic S, Čičin-Šain L. MCMV based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. Cell Mol Immunol. 2022 Feb;19(2):234-244. doi.org/10.1038/s41423-021-00814-5.
26. Marcotte H, Piralla A, Zuo F, Du F, Cassaniti I, Wan H, Kumagai-Braesh M, Andrell J, Percivalle E, Sammartino JC, Wang Y, Vlachiotis S, Attevall J, Bergami F, Ferrari A, Colaneri M, Vecchia M, Sambo M, Zuccaro V, Asperges E, Bruno R, Oggionni T, Meloni F, Abolhassanni H, Bertoglio F, Schubert M, Calzolai L, Varani L, Hust M, Xue Y, Hammarström L, Baldanti F, Pan-Hammarström Q. Immunity to SARS-CoV-2 up to 15 months after infection. iScience. 2022 Feb 18;25(2):103743. doi.org/10.1016/j.isci.2022.103743.
27. Sherina N*, Piralla A*, Du L*, Wan H*, Kumagai-Braesch M, Andréll J, Braesch-Andersen S, Cassaniti I, Percivalle E, Sarasini A, Bergami F, Di Martino R, Colaneri M, Vecchia M, Sambo M, Zuccaro V, Bruno R, Sachs M, Oggionni T, Meloni F, Abolhassani H, Bertoglio F, Schubert M, Byrne-Steele M, Han J, Hust M, Xue Y, Hammarström L, Baldanti F, Marcotte H, Pan-Hammarström Q. Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection. Med (N Y). 2021 Mar 12;2(3):281-295.e4. doi.org/10.1016/j.medj.2021.02.001.
28. Schubert M, Nimtz M, Bertoglio F, Schmelz S, Lukat P, van den Heuvel J. Reproducible and Easy Production of Mammalian Proteins by Transient Gene Expression in High Five Insect Cells. Methods Mol Biol. 2021;2305:129-140. doi.org/10.1007/978-1-0716-1406-8_6
29. Brondino N, Bertoglio F, Forneris F, Faravelli S, Borghesi A, Damiani S, Provenzani U, Nola M, Olivola M, Caviglia M, Politi P, Fusar-Poli L, Fusar-Poli P. A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects. Brain Sci. 2021 Jun 28;11(7):860. doi.org/10.3390/brainsci11070860.
30. Roth KDR, Wenzel EV, Ruschig M, Steinke S, Langreder N, Heine PA, Schneider KT, Ballmann R, Fühner V, Kuhn P, Schirrmann T, Frenzel A, Dübel S, Schubert M, Moreira GMSG, Bertoglio F, Russo G, Hust M. Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy. Front Cell Infect Microbiol. 2021 Jul 7;11:697876. doi.org/10.3389/fcimb.2021.697876
31. Korn J, Schäckermann D, Kirmann T, Bertoglio F, Steinke S, Heisig J, Ruschig M, Rojas G, Langreder N, Wenzel EV, Roth KDR, Becker M, Meier D, van den Heuvel J, Hust M, Dübel S, Schubert M. Baculovirus-free insect cell expression system for antibody and antigen production. Sci Rep. 2020 Dec 7;10(1):21393. doi.org/10.1038/s41598-020-78425-9
* Shared first authorship
§ First and corresponding author
Nanomaterial field-related publications
32. Peneda Pacheco D, Bertoglio F, Butnarasu C, Suarez Vargas N, Guagliano G, Ziccarelli A, Briatico-Vangosa F, Ruzzi V, Buzzaccaro S, Piazza R, van Uden S, Crotti E, Visentin S, Visai L, Petrini P. Heterogeneity governs 3D-cultures of clinically relevant microbial communities. Adv. Funct. Mater. 2023, 2306116. doi.org/10.1002/adfm.202306116
33. Oriano M, Zorzetto L, Guagliano G, Bertoglio F, van Uden S, Visai L, Petrini P. The Open Challenge of in vitro Modeling Complex and Multi-Microbial Communities in Three-Dimensional Niches. Front Bioeng Biotechnol. 2020 Oct 20;8:539319. doi.org/10.3389/fbioe.2020.539319
34. Villani M*, Bertoglio F*, Restivo E, Bruni G, Iervese S, Arciola CR, Carulli F, Iannace S, Bertini F, Visai L. Polyurethane-Based Coatings with Promising Antibacterial Properties. Materials (Basel). 2020 Sep 25;13(19):4296. doi: 10.3390/ma13194296.
35. Lizundia E, Armentano I, Luzi F, Bertoglio F, Restivo E, Visai L, Torre L, Puglia D. Synergic Effect of Nanolignin and Metal Oxide Nanoparticles into Poly(l-lactide) Bionanocomposites: Material Properties, Antioxidant Activity, and Antibacterial Performance.
ACS Appl Bio Mater. 2020 Aug 17;3(8):5263-5274. doi.org/10.1021/acsabm.0c00637.
36. Bertoglio F§, De Vita L, D'Agostino A, Diaz Fernandez Y, Falqui A, Casu A, Merli D, Milanese C, Rossi S, Taglietti A, Visai L, Pallavicini P. Increased Antibacterial and Antibiofilm Properties of Silver Nanoparticles Using Silver Fluoride as Precursor. Molecules. 2020 Jul 31;25(15):3494. doi.org/10.3390/molecules25153494.
37. Villani M, Consonni R, Canetti M, Bertoglio F, Iervese S, Bruni G, Visai L, Iannace S, Bertini F. Polyurethane-Based Composites: Effects of Antibacterial Fillers on the Physical-Mechanical Behavior of Thermoplastic Polyurethanes. Polymers (Basel). 2020 Feb 6;12(2):362. doi.org/10.3390/polym12020362.
38. Bloise N, Petecchia L, Ceccarelli G, Fassina L, Usai C, Bertoglio F, Balli M, Vassalli M, Cusella De Angelis MG, Gavazzo P, Imbriani M, Visai L. The effect of pulsed electromagnetic field exposure on osteoinduction of human mesenchymal stem cells cultured on nano-TiO2 surfaces. PLoS One. 2018 Jun 14;13(6):e0199046. doi.org/10.1371/journal.pone.0199046.
39. Brondino N, Fusar-Poli L, Rocchetti M, Bertoglio F, Bloise N, Visai L, Politi P. BDNF levels are associated with autistic traits in the general population. Psychoneuroendocrinology. 2018 Mar;89:131-133. doi.org/10.1016/j.psyneuen.2018.01.008.
40. Yang W, Fortunati E, Bertoglio F, Owczarek JS, Bruni G, Kozanecki M, Kenny JM, Torre L, Visai L, Puglia D. Polyvinyl alcohol/chitosan hydrogels with enhanced antioxidant and antibacterial properties induced by lignin nanoparticles. Carbohydr Polym. 2018 Feb 1;181:275-284. doi.org/10.1016/j.carbpol.2017.10.084.
41. Bertoglio F§, Bloise N, Oriano M, Petrini P, Sprio S, Imbriani M, Tampieri A, Visai L. Treatment of Biofilm Communities: An Update on New Tools from the Nanosized World. Applied Sciences. 2018; 8(6):845. doi.org/10.3390/app8060845
42. Pallavicini P, Arciola CR, Bertoglio F, Curtosi S, Dacarro G, D'Agostino A, Ferrari F, Merli D, Milanese C, Rossi S, Taglietti A, Tenci M, Visai L. Silver nanoparticles synthesized and coated with pectin: An ideal compromise for anti-bacterial and anti-biofilm action combined with wound-healing properties. J Colloid Interface Sci. 2017 Jul 15;498:271-281. doi.org/10.1016/j.jcis.2017.03.062.
43. Yalcinkaya EE, Puglia D, Fortunati E, Bertoglio F, Bruni G, Visai L, Kenny JM. Cellulose nanocrystals as templates for cetyltrimethylammonium bromide mediated synthesis of Ag nanoparticles and their novel use in PLA films.
Carbohydr Polym. 2017 Feb 10;157:1557-1567. doi.org/10.1016/j.carbpol.2016.11.038.
44. Vercellino M, Ceccarelli G, Cristofaro F, Balli M, Bertoglio F, Bruni G, Benedetti L, Avanzini MA, Imbriani M, Visai L. Nanostructured TiO₂ Surfaces Promote Human Bone Marrow Mesenchymal Stem Cells Differentiation to Osteoblasts. Nanomaterials (Basel). 2016 Jun 24;6(7):124. doi.org/10.3390/nano6070124.
* Shared first authorship
§ First and corresponding author